Effects of different hyaluronic acid products on synovial fluid levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in knee osteoarthritis

Annals of Clinical and Laboratory Science

Volumn 34, Issue 3, 2004, Pages 330-335

  Karatay, Saliha ^a,b   Kiziltunc, Ahmet ^a   Yildirim, Kadir ^a   Karanfil, Rabia Cerrah ^a   Senel, Kazim ^a  

^a ATATURK UNIVERSITY   (Turkey)

^b ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Hyaluronic acid; ICAM 1; Knee osteoarthritis; Molecular weight; Synovial fluid; VCAM 1

Indexed keywords

HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; MALE; PAIN ASSESSMENT; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNOVIAL FLUID LEVEL;

AGED; FEMALE; HUMANS; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE-1; MALE; OSTEOARTHRITIS, KNEE; SEVERITY OF ILLNESS INDEX; SYNOVIAL FLUID; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 4444324117     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Martel-Pelletier J, Alaaeddine N, Pelletier JP. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci 1999;15:694-703.
2. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001;44:1237-1247.
3. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997;24:365-371.
4. Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D, Walsh DA. Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum 2003;48:2173-2177.
5. Ulbrich H, Eriksson EE, Lindbom L. Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease. Trends Pharmacol Sci 2003;24:640-647.
6. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
7. Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. Clin Orthop 2001;385:130-143.
8. Conrozier T, Mathieu P, Schott AM, Laurent I, Hajri T, Crozes P, Grand P, Laurent H, Marchand F, Meignan F, Noel E, Rozand Y, Savoye JF, Vignon E. Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis. Joint Bone Spine 2003;70:128-133.
9. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002;32:10-37.
10. Karlsson J, Sjogren LS, Lohmander LS. Comparison of two hyaluronan drugs and placebo in patients with knee osteoarthritis. A controlled, randomized, double-blind, parallel-design multicentre study. Rheumatology 2002;41:1240-1248.
11. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003;5:54-67.
12. Herrero-Beaumont G, Guerrero R, Sanchez-Pernaute O, Acebes C, Palacios I, Mas S, Rodriguez I, Egido J, Vivanco F. Cartilage and bone biological markers in the synovial fluid of osteoarthritic patients after hyaluronan injections in the knee. Clin Chim Acta 2001;308:107-115.
13. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid. Clin Exp Rheumatol 1994;12:75-82.
14. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039-1049.
15. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:94-502.
16. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-1840.
17. Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003;290:3115-3121.
18. Ghosh P, Read R, Armstrong S, Wilson D, Marshall R, McNair P. The effects of intraarticular administration of hyaluronan in a model of early osteoarthritis in sheep. I. Gait analysis and radiological and morphological studies. Semin Arthritis Rheum 1993;22(Suppl 1):18-30.
19. Wen DY. Intra-articular hyaluronic acid injections for knee osteoarthritis. Am Fam Physician 2000;62:565-570.
20. Marshall KW. Viscosupplementation for osteoarthritis: current status, unresolved issues, and future directions. J Rheumatol 1998;25:2056-2058.
21. Notoya K, Jovanovic DV, Reboul P, Martel-Pelletier J, Mineau F, Pelletier JP. The induction of cell death in human osteoarthritis chondrocytes by nitric oxide is related to the production of prostaglandin E2 via the induction of cyclooxygenase-2. J Immunol 2000;165:3402-3410.
22. Yamashita I, Gomis A, Pawlak M, Balazs EA, Schmidt RF, Belmonte C. Effects of different molecular weight elastoviscous hyaluronan solutions on articular nociceptive afferents. Arthritis Rheum 2004;50:314-326.
23. Fraser JR, Kimpton WG, Pierscionek BK, Cahill RN. The kinetics of hyaluronan in normal and acutely inflamed synovial joints: observations with experimental arthritis in sheep. Semin Arthritis Rheum 1993;22(Suppl 1):9-17.
24. Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T. The effect of hyaluronan on interleukin-1 alpha-induced prostaglandin E2 production in human osteoarthritic synovial cells. Agents Actions 1992;37:155-156.
25. 14C]arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol 1992;60:79-84.
26. Larsen NE, Lombard KM, Parent EG, Balazs EA. Effect of hylan on cartilage and chondrocyte cultures. J Orthop Res 1992;10:23-32.
27. Feinberg RN, Beebe DC. Hyaluronate in vasculogenesis. Science 1983;220:1177-1179.
28. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 1993;20(Suppl 39):3-9.
29. Kakimoto K, Nakamura T, Ishii K, Takashi T, Iigou H, Yagita H, Okumura K, Onoue K. The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis. Cell Immunol 1992;142:326-337.
30. Iigo Y, Takashi T, Tamatani T, Miyasaka M, Higashida T, Yagita H, Okumura K, Tsukada W. ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J Immunol 1991;147:4167-4171.